Menu
Real-life data on the efficacy and safety of PCSK9 inhibitors are critically important and thus we decided within the International Lipid Expert Panel to create the ILEP CEE/SE PCSK9 Registry. We have invited Principal Investigators from 19 countries in order to collect as many data as possible. We believe that our commitment will contribute in improving the reimbursement programs in invited countries.
In this section we will publish news about the PCSK9 ILEP Registry.
Principal Investigator of Estonia
Principal Investigator of Latvia
Principal Investigator of Latvia
Principal Investigator of Lithuania
Principal Investigator of Poland
Principal Investigator of Poland
Principal Investigator of Belarus
Principal Investigator of Russia
Principal Investigator of Czech Republic
Principal Investigator of Czech Republic
Principal Investigator of Slovakia
Principal Investigator of Hungary
Principal Investigator of Greece
Principal Investigator of Romania
Principal Investigator of Romania
Principal Investigator of Bulgaria
Principal Investigator of Slovenia
Principal Investigator of Serbia
Principal Investigator of Croatia
Principal Investigator of Albania
Principal Investigator of Bosnia and Herzegovina
Principal Investigator of Ukraine
Principal Investigator of Kosovo
Principal Investigator of Germany
In case of any questions, please contact the ILEP Secretary – Patrycja Lewandowicz: